Business Context and Reporting Period
Company: Exagen Inc. (XGN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Exagen is a medical technology company focused on the design, development, and commercialization of testing products under the AVISE® brand for the differential diagnosis, prognosis, and monitoring of complex rheumatic and autoimmune diseases, including Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The company operates a single reporting segment and performs all testing in its Vista, California laboratory.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $55,641 | $52,548 |
| Costs of Revenue | $22,529 | $23,092 |
| Gross Margin | $33,112 | $29,456 |
| Gross Margin % | 59.5% | 56.1% |
| Operating Expenses | $46,748 | $52,293 |
| Net Loss | $(15,115) | $(23,689) |
| Cash and Cash Equivalents (Year End) | $22,036 | $36,493 |
| Accumulated Deficit | $(294,331) | $(279,216) |
Debt: As of December 31, 2024, the company had $18.5 million in principal and paid-in-kind (PIK) loans outstanding under its Amended Loan Agreement with Innovatus Life Sciences Lending Fund I, LP. The loan matures in December 2026, with principal repayment commencing in April 2026.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5.9% year-over-year to $55.6 million, driven primarily by improved Average Selling Price (ASP) and cash collections related to prior periods. This growth occurred despite an 11% decline in AVISE® CTD test volume (122,883 tests in 2024 vs. 137,650 in 2023).
- Margin Expansion: Gross margin improved by 340 basis points to 59.5%, attributed to ASP improvements and reductions in materials, supplies, and overhead expenses.
- Expense Reduction: Operating expenses decreased 10.6% to $46.7 million. Selling, General, and Administrative (SG&A) expenses dropped 12.8%, largely due to a $1.8 million decrease in stock-based compensation and the absence of a $1.5 million lease assignment loss recorded in 2023.
- Net Loss Improvement: Net loss narrowed by 36.2% to $15.1 million, reflecting the combined impact of revenue growth and significant operating expense reductions.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management is executing an operational turnaround strategy focused on revenue growth, gross margin expansion, and reduced cash burn. Key initiatives include:
- Product Enhancements: In January 2025, the company launched new SLE and RA biomarker assays on the AVISE® CTD platform. Management expects these additions to drive ASP growth, margin expansion, and increased demand.
- Profitability Path: The company aims to achieve positive Adjusted EBITDA in the near term through continued gross margin enhancements and operating expense efficiencies.
- Liquidity: Management believes existing cash ($22.0 million) and anticipated revenue will fund operations for at least the next 12 months.
Risks and Contingencies
- Reimbursement Uncertainty: Revenue depends heavily on third-party payor coverage. The company faces challenges with commercial payor claim processing and unfavorable medical policies. Medicare coverage for the AVISE® Lupus test under a new PLA code is pending a Local Coverage Determination (LCD).
- Regulatory Changes (FDA LDT Rule): The FDA's final rule on Laboratory Developed Tests (LDTs), effective July 2024, may require the company to obtain premarket clearance or approval for its tests, potentially incurring significant costs and delays. Litigation challenging this rule is ongoing.
- Debt Covenants: The company must maintain minimum liquidity of $2.0 million and meet revenue covenants. Failure to comply could trigger an event of default, allowing the lender to accelerate debt repayment.
- Supply Chain: The company relies on sole suppliers for critical reagents and a sole fulfillment center, creating potential operational risks.
- Legal Proceedings: A qui tam lawsuit regarding historical specimen processing arrangements remains pending, though a related investigation was settled in October 2023 for $0.7 million.
Investor Verification Checklist
- Reimbursement Status: Verify the status of the pending Local Coverage Determination (LCD) for the AVISE® Lupus test with Medicare and the success of commercial payor contract negotiations.
- Volume vs. ASP Dynamics: Monitor whether the decline in test volume (11% in 2024) stabilizes or reverses following the January 2025 biomarker launch, and confirm if ASP growth is sustainable.
- Debt Maturity: Assess the company's ability to refinance or repay the $18.5 million term loan principal due in April 2026, given the current cash burn rate.
- Regulatory Compliance: Track the outcome of the litigation challenging the FDA's LDT final rule and the company's specific compliance timeline and cost estimates.
- Supplier Concentration: Confirm the stability of relationships with sole-source suppliers for critical reagents, which accounted for approximately 71% and 26% of diagnostic testing supplies in 2024.